eligibility_summary
Include: Adults ≥18, ECOG 0–1, ≥3‑mo life expectancy, consent/compliant, contraception required, women of childbearing potential: negative pregnancy, not lactating. Cancer: Phase Ia/Ib—unresectable/metastatic solid tumors after SOC failure/intolerance or no SOC, Phase II—unresectable/metastatic SCLC after platinum + ICI. Exclude: >2 prior primaries, prior anti‑tumor/TCM/investigational therapy, unstable brain mets/leptomeningeal disease, unresolved ≥G2 AEs, major surgery/trauma or planned surgery, live vaccine, non‑traumatic bleeding, systemic steroids/immunosuppression, significant lung disease, ILD/pneumonitis.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: MHB088C for Injection—an antibody-drug conjugate (ADC) administered IV every 2 or 3 weeks. Mechanism: Specific antigen, linker, and payload are not disclosed in the record. As an ADC, it uses a monoclonal antibody to bind a tumor-associated cell-surface antigen, undergoes internalization, and releases an intracellular cytotoxic payload to kill cancer cells, pharmacokinetics and immunogenicity are evaluated. Targets/cells: malignant solid tumor cells expressing the (unspecified) antigen, no specific immune checkpoint or signaling pathway is named. Population: adults with advanced/metastatic solid tumors (Phase I), Phase II focuses on relapsed/refractory SCLC after platinum chemotherapy and immune checkpoint inhibitors. Objective: assess safety/tolerability and preliminary efficacy.